Can naproxen and domperidone be given to a 13-year-old?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Safety of Naproxen and Domperidone in a 13-Year-Old

Naproxen can be safely used in a 13-year-old, but domperidone should only be used with caution in children over 12 years of age for short-term treatment of nausea and vomiting.

Naproxen Use in 13-Year-Olds

Naproxen is approved for use in pediatric patients over 2 years of age, with established safety and efficacy data for juvenile arthritis 1. The FDA-approved dosing guidelines state:

  • For children over 2 years: 2.5-5 mg/kg as a single dose
  • Total daily dose should not exceed 15 mg/kg/day
  • Naproxen suspension is typically used for precise pediatric dosing

Safety considerations for naproxen in adolescents:

  • Well-tolerated in pediatric patients over 2 years of age
  • Primarily excreted by the kidney, so renal function should be monitored
  • As with all NSAIDs, there are risks of gastrointestinal effects, though these are less common in younger patients compared to elderly patients 1

Domperidone Use in 13-Year-Olds

Domperidone use in pediatric patients requires more caution:

  • Current guidelines restrict its use to relief of nausea and vomiting in children older than 12 years for a short period of time 2
  • Since the patient is 13 years old, they meet the minimum age requirement, but careful consideration is needed

Safety concerns with domperidone:

  • Cardiac safety issues have been identified, including QT prolongation and potential arrhythmias 3
  • In 2014, safety warnings were issued in multiple countries regarding cardiac risks in children 4
  • Should not be administered to patients with:
    • Pre-existing QT prolongation
    • Patients receiving CYP3A4 inhibitors
    • Electrolyte abnormalities
    • Other risk factors for QT prolongation 3

Evidence for Efficacy in Pediatrics

  • A 2019 randomized controlled trial found that low-dose domperidone (0.25 mg/kg three times daily) was not significantly better than placebo for treating nausea and vomiting in children with acute gastroenteritis 5
  • For gastroesophageal reflux disease (GERD) in children, a Cochrane review found no significant benefit of domperidone 6

Recommendations for Clinical Practice

If considering domperidone for a 13-year-old:

  1. Use only for short-term treatment of nausea and vomiting (not for GERD or other off-label indications)
  2. Prescribe the lowest effective dose (0.25 mg/kg three times daily)
  3. Limit duration to less than 7 days 4
  4. Screen for cardiac risk factors and drug interactions before prescribing
  5. Monitor for adverse effects, particularly cardiac symptoms

For naproxen in a 13-year-old:

  1. Use appropriate weight-based dosing (2.5-5 mg/kg per dose)
  2. Do not exceed 15 mg/kg/day total daily dose
  3. Monitor for gastrointestinal symptoms
  4. Consider using with food to minimize GI effects

Key Cautions

  • Domperidone is used off-label in many countries for GERD and gastroparesis, but evidence for efficacy in children is limited 2
  • Cardiac safety concerns have led to restricted use of domperidone in pediatric patients
  • Naproxen is generally safe in adolescents but should be used at the lowest effective dose for the shortest duration needed

When prescribing these medications for a 13-year-old, the benefits must clearly outweigh the risks, particularly for domperidone given its cardiac safety profile and limited evidence of efficacy in pediatric patients.

References

Research

Drugs in Focus: Domperidone.

Journal of pediatric gastroenterology and nutrition, 2023

Research

Domperidone prescribing patterns in pediatric patients before and after safety warning in South Korea.

International journal of clinical pharmacology and therapeutics, 2020

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.